Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging

阶段(地层学) 癌症 AJCC分段系统 医学 癌症分期 监测、流行病学和最终结果 流行病学 腺癌 肿瘤科 结直肠癌 癌症登记处 内科学 外科 登台系统 古生物学 生物
作者
J. B. O'Connell,Melinda A. Maggard,Clifford Y. Ko
出处
期刊:Journal of the National Cancer Institute [Oxford University Press]
卷期号:96 (19): 1420-1425 被引量:1557
标识
DOI:10.1093/jnci/djh275
摘要

Background: The recently revised American Joint Committee on Cancer (AJCC) sixth edition cancer staging system increased the stratification within colon cancer stages II and III defined by the AJCC fifth edition system. Using nationally representative Surveillance, Epidemiology, and End Results (SEER) data, we compared survival rates associated with colon cancer stages defined according to both AJCC systems. Methods: Using SEER data (from January 1, 1991, through December 31, 2000), we identified 119 363 patients with colon adenocarcinoma and included all patients in two analyses by stages defined by AJCC fifth and sixth edition systems. Tumors were stratified by SEER’s “extent of disease” and “number of positive [lymph] nodes” coding schemes. Kaplan–Meier analyses were used to compare overall and stage-specific 5-year survival. All statistical tests were two-sided. Results: Overall 5-year survival was 65.2%. According to stages defined by the AJCC fifth edition system, 5-year stage-specific survivals were 93.2% for stage I, 82.5% for stage II, 59.5% for stage III, and 8.1% for stage IV. According to stages defined by the AJCC sixth edition system, 5-year stage-specific survivals were 93.2% for stage I, 84.7% for stage IIa, 72.2% for stage IIb, 83.4% for stage IIIa, 64.1% for stage IIIb, 44.3% for stage IIIc, and 8.1% for stage IV. Under the sixth edition system, 5-year survival was statistically significantly better for patients with stage IIIa colon cancer (83.4%) than for patients with stage IIb disease (72.2%) (P<.001). Conclusions: The AJCC sixth edition system for colon cancer stratifies survival more distinctly than the fifth edition system by providing more substages. The association of stage IIIa colon cancer with statistically significantly better survival than stage IIb in the new system may reflect current clinical practice, in which stage III patients receive chemotherapy but stage II patients generally do not.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Ayo发布了新的文献求助10
1秒前
SciGPT应助小康长不大采纳,获得10
1秒前
czz发布了新的文献求助10
2秒前
Abelsci完成签到,获得积分0
3秒前
小罗在前行完成签到,获得积分20
3秒前
结实的丹雪完成签到,获得积分10
4秒前
archer01发布了新的文献求助30
4秒前
毓凡发布了新的文献求助10
5秒前
orixero应助庸人自扰采纳,获得10
5秒前
超然度陈发布了新的文献求助10
6秒前
7秒前
陈泽冉完成签到,获得积分10
12秒前
熬熬就出头了完成签到,获得积分10
12秒前
12秒前
电闪完成签到,获得积分10
13秒前
周梦蝶完成签到,获得积分10
14秒前
Alan完成签到,获得积分10
15秒前
bo关闭了bo文献求助
17秒前
庸人自扰发布了新的文献求助10
17秒前
Ava应助archer01采纳,获得10
18秒前
慕青应助songnvshi采纳,获得10
19秒前
SUR完成签到,获得积分0
21秒前
cocolu应助darkage采纳,获得10
22秒前
23秒前
谦让寻凝完成签到 ,获得积分10
24秒前
24秒前
桐桐应助毓凡采纳,获得10
25秒前
赤橙发布了新的文献求助10
26秒前
29秒前
汉堡包应助qi采纳,获得10
29秒前
科目三应助友好的谷兰采纳,获得10
30秒前
涛1118完成签到,获得积分20
30秒前
30秒前
嘿嘿完成签到,获得积分10
30秒前
30秒前
31秒前
33秒前
缥缈耷发布了新的文献求助10
33秒前
涛1118发布了新的文献求助10
33秒前
高分求助中
Licensing Deals in Pharmaceuticals 2019-2024 3000
Cognitive Paradigms in Knowledge Organisation 2000
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger Heßler, Claudia, Rud 1000
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 1000
Natural History of Mantodea 螳螂的自然史 1000
A Photographic Guide to Mantis of China 常见螳螂野外识别手册 800
How Maoism Was Made: Reconstructing China, 1949-1965 800
热门求助领域 (近24小时)
化学 医学 材料科学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 量子力学 冶金 电极
热门帖子
关注 科研通微信公众号,转发送积分 3316416
求助须知:如何正确求助?哪些是违规求助? 2948109
关于积分的说明 8539240
捐赠科研通 2624069
什么是DOI,文献DOI怎么找? 1435722
科研通“疑难数据库(出版商)”最低求助积分说明 665672
邀请新用户注册赠送积分活动 651532